Cargando…
Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma
SIMPLE SUMMARY: Pancreatic adenocarcinoma (PDAC) is a disease with an incredibly grim prognosis. Most patients die within one year of receiving the diagnosis. There are currently very few tools to help the clinician decide between treatment options and evaluate prognosis at an individual level. The...
Autores principales: | Stubbe, Benjamin Emil, Henriksen, Stine Dam, Madsen, Poul Henning, Larsen, Anders Christian, Krarup, Henrik Bygum, Pedersen, Inge Søkilde, Johansen, Martin Nygård, Thorlacius-Ussing, Ole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616084/ https://www.ncbi.nlm.nih.gov/pubmed/34830873 http://dx.doi.org/10.3390/cancers13225717 |
Ejemplares similares
-
Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma
por: Stubbe, Benjamin Emil, et al.
Publicado: (2023) -
Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma
por: Henriksen, Stine Dam, et al.
Publicado: (2017) -
Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma
por: Henriksen, Stine Dam, et al.
Publicado: (2016) -
The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer
por: Rasmussen, Simon Ladefoged, et al.
Publicado: (2018) -
Hypermethylated DNA, a circulating biomarker for colorectal cancer detection
por: Rasmussen, Simon Ladefoged, et al.
Publicado: (2017)